Denmark may halt Ozempic subsidy for type 2 diabetes patients

Denmark should stop subsidising the use of Ozempic and other so-called GLP-1 drugs for patients suffering from type 2 diabetes, and instead pay for cheaper drugs as a preferred first option, a public commission said in a recommendation issued on Tuesday. The proposal will be subject to a hearing until Oct. 8, after which a decision will be made by the Danish Medicines Agency. While GLP-1 drugs are significantly more expensive than other options, there is no general advantage in the treatment of patients suffering from type 2 diabetes, the commission said in a statement.